Zhejiang Shouxiangu Pharm Co - Asset Resilience Ratio

Latest as of March 2026: 12.69%

Zhejiang Shouxiangu Pharm Co (603896) has an Asset Resilience Ratio of 12.69% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 603896 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥408.33 Million

≈ $59.75 Million USD Cash + Short-term Investments

Total Assets

CN¥3.22 Billion

≈ $470.95 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2015–2025)

This chart shows how Zhejiang Shouxiangu Pharm Co's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Zhejiang Shouxiangu Pharm Co assets under control.

Liquid Assets Composition Over Time

This chart breaks down Zhejiang Shouxiangu Pharm Co's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Zhejiang Shouxiangu Pharm Co total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥408.33 Million	12.69%
Total Liquid Assets	CN¥408.33 Million	12.69%

Asset Resilience Insights

Moderate Liquidity: Zhejiang Shouxiangu Pharm Co has 12.69% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Zhejiang Shouxiangu Pharm Co Industry Peers by Asset Resilience Ratio

Compare Zhejiang Shouxiangu Pharm Co's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Celldex Therapeutics Inc NASDAQ:CLDX	Biotechnology	81.32%
MBX Biosciences, Inc. Common Stock NASDAQ:MBX	Biotechnology	87.20%
Neuren Pharmaceuticals Ltd AU:NEU	Biotechnology	90.43%
Savara Inc NASDAQ:SVRA	Biotechnology	68.30%
Chengdu Kanghua Biological Products SHE:300841	Biotechnology	1.19%

Annual Asset Resilience Ratio for Zhejiang Shouxiangu Pharm Co (2015–2025)

The table below shows the annual Asset Resilience Ratio data for Zhejiang Shouxiangu Pharm Co.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	10.85%	CN¥356.16 Million ≈ $52.12 Million	CN¥3.28 Billion ≈ $480.19 Million	-0.15pp
2024-12-31	11.01%	CN¥344.69 Million ≈ $50.44 Million	CN¥3.13 Billion ≈ $458.19 Million	+9.96pp
2022-12-31	1.05%	CN¥30.00 Million ≈ $4.39 Million	CN¥2.86 Billion ≈ $417.95 Million	-5.57pp
2021-12-31	6.62%	CN¥130.00 Million ≈ $19.02 Million	CN¥1.96 Billion ≈ $287.17 Million	+3.68pp
2020-12-31	2.94%	CN¥50.00 Million ≈ $7.32 Million	CN¥1.70 Billion ≈ $248.70 Million	-11.86pp
2019-12-31	14.80%	CN¥198.50 Million ≈ $29.05 Million	CN¥1.34 Billion ≈ $196.20 Million	+12.18pp
2018-12-31	2.62%	CN¥31.22 Million ≈ $4.57 Million	CN¥1.19 Billion ≈ $174.36 Million	-20.91pp
2017-12-31	23.53%	CN¥218.00 Million ≈ $31.90 Million	CN¥926.34 Million ≈ $135.55 Million	+21.79pp
2016-12-31	1.74%	CN¥10.67 Million ≈ $1.56 Million	CN¥612.10 Million ≈ $89.57 Million	-0.82pp
2015-12-31	2.56%	CN¥15.50 Million ≈ $2.27 Million	CN¥605.91 Million ≈ $88.66 Million	--

pp = percentage points

About Zhejiang Shouxiangu Pharm Co

SHG:603896 China Biotechnology

Market Cap

$409.32 Million

CN¥2.80 Billion CNY

Market Cap Rank

#13407 Global

#4006 in China

Share Price

CN¥14.11

Change (1 day)

+0.79%

52-Week Range

CN¥12.95 - CN¥22.30

All Time High

CN¥56.07